<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Remdesivir: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Remdesivir: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Remdesivir: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="127396" href="/d/html/127396.html" rel="external">see "Remdesivir: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="128095" href="/d/html/128095.html" rel="external">see "Remdesivir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54829651"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Veklury</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54783414"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Veklury</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54175141"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent</li></ul></div>
<div class="block doa drugH1Div" id="F54175145"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9116062-427d-4715-8eda-5d582e2630c5">COVID-19, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hospitalized patients: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In general, guidelines recommend use in conjunction with dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2','lexi-content-ref-33555780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2','lexi-content-ref-33555780'])">Ref</a></span>); may be used as monotherapy in select patients (eg, requiring minimal conventional oxygen, not requiring oxygen supplementation but at high risk of severe COVID-19) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg as a single dose on day 1, followed by 100 mg once daily. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2'])">Ref</a></span>). Initiate as soon as possible after the diagnosis of symptomatic COVID-19 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33555780','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33555780','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonhospitalized patients with high risk of progression to severe illness: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg as a single dose on day 1, followed by 100 mg once daily on days 2 and 3. Initiate as soon as possible after COVID-19 diagnosis and within 7 days of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34937145','lexi-content-ref-NIH.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34937145','lexi-content-ref-NIH.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54331461"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable: No supplemental dose or dosage adjustment necessary; may be administered without regard to timing of dialysis sessions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F54368299"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> Although randomized, controlled trials excluded patients with baseline ALT/AST ≥5 times ULN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32459919','lexi-content-ref-32706859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32459919','lexi-content-ref-32706859'])">Ref</a></span>), remdesivir has been successfully used in a limited number of patients with baseline AST/ALT &gt;5 times ULN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33763917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33763917'])">Ref</a></span>). While AST/ALT elevations have been observed in patients treated with remdesivir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32459919','lexi-content-ref-32725454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32459919','lexi-content-ref-32725454'])">Ref</a></span>) (requiring discontinuation in ~3% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32459919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32459919'])">Ref</a></span>)) an exploratory analysis to determine the risk of remdesivir-induced liver injury (defined as one of the following: total bilirubin, ALT or AST &gt;2 times ULN, or INR &gt;1.7) did not find an increased risk of remdesivir-induced liver injury following exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35318694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35318694'])">Ref</a></span>). Additionally, elevated transaminases are a known clinical feature of COVID-19 infection, and therefore, use of remdesivir should not be avoided solely based on the presence of elevated liver chemistries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial or dose titration in patients with preexisting liver cirrhosis: Note: </b>Baseline liver chemistries should be obtained prior to initiation in hospitalized patients and periodically (eg, every 1 to 2 days) during treatment and as needed in outpatients if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class A to C:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35045989','lexi-content-ref-33362383','lexi-content-ref-33712855','lexi-content-ref-33763917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35045989','lexi-content-ref-33362383','lexi-content-ref-33712855','lexi-content-ref-33763917'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A to C:</b></p>
<p style="text-indent:-2em;margin-left:6em;">ALT ≤10 times ULN: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33712855','lexi-content-ref-33763917','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33712855','lexi-content-ref-33763917','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ALT &gt;10 times ULN: Consider discontinuation of remdesivir. If therapy is continued, no dosage adjustment necessary; however, in patients also experiencing signs/symptoms of liver inflammation, remdesivir therapy should be discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute hepatotoxicity during treatment (eg, requiring hospitalization)</b>
<b>: </b>
<b>Note: </b>Baseline liver chemistries should be obtained prior to initiation in hospitalized patients and periodically (eg, every 1 to 2 days) during treatment and as needed in outpatient if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ALT ≤10 times ULN: No dosage adjustment necessary; however, in patients also experiencing signs/symptoms of liver inflammation, must weigh risks/benefits of continuation of remdesivir therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ALT &gt;10 times ULN: Consider discontinuation of remdesivir. If therapy is continued, no dosage adjustment necessary; however, in patients also experiencing signs/symptoms of liver inflammation, remdesivir therapy should be discontinued.</p></div>
<div class="block doe drugH1Div" id="F54175146"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F54201371"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="127396" href="/d/html/127396.html" rel="external">see "Remdesivir: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c62a0f-2c54-461c-b0f2-d15d96c3fccb">COVID-19, hospitalized patients; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients; treatment: Note:</b> Initiate as soon as possible after diagnosis of symptomatic COVID-19. Duration is generally 5 days or until hospital discharge, whichever is first, but may be extended up to 10 days if patient does not clinically improve or requires extracorporeal membrane oxygenation or mechanical ventilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32918548','lexi-content-ref-32459919','lexi-content-ref-NIH.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32918548','lexi-content-ref-32459919','lexi-content-ref-NIH.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 kg, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">3 to &lt;40 kg: Lyophilized powder only: IV: Loading dose: 5 mg/kg/dose on day 1, followed by 2.5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32918548','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32918548','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: Injection solution or lyophilized powder: IV: Loading dose: 200 mg on day 1, followed by 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32918548','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32918548','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f9ed25a0-226e-4523-a78a-04ceb07e016f">COVID-19, nonhospitalized patients; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, nonhospitalized patients; treatment: Note:</b> Reserve for the treatment of mild to moderate COVID-19 in patients at high risk for progression to severe disease, including hospitalization or death; <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fpeople-with-medical-conditions.html&amp;token=dp%2Bu1JIS0z56iPYhxy2iH6As6HG8Wy5KTscyOOyd0dt6v1sI5e58zhsbJGrR72IVlu%2BsRt4VyjJdD6IxQ8r4XPWnorFdySfw3fUyErJsE4Z1vuNDMLXdolJp%2FGQCW6Ts&amp;TOPIC_ID=127259" target="_blank">refer to the CDC</a> for more information on patients at high risk for progression to severe disease. Initiate as soon as possible after diagnosis of symptomatic COVID-19 and within 7 days of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-NIH.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-NIH.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 kg, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">3 to &lt;40 kg: Lyophilized powder only: IV: Loading dose: 5 mg/kg/dose on day 1, followed by 2.5 mg/kg/dose once daily on days 2 and 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: Injection solution or lyophilized powder: IV: Loading dose: 200 mg on day 1, followed by 100 mg once daily on days 2 and 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34937145','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34937145','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F54340244"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants ≥3 kg, Children, and Adolescents: No dosage adjustment recommended for any degree of kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis: </b>Infants, Children, and Adolescents: No dosage adjustment recommended; may be administered without regard to timing of dialysis sessions. Not significantly dialyzable.</p></div>
<div class="block dohp drugH1Div" id="F54374535"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥3 kg, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment: </i>There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ALT &gt;10 times the ULN and asymptomatic: Consider discontinuing remdesivir.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT elevation AND signs or symptoms of liver inflammation: Discontinue remdesivir.</p></div>
<div class="block arsc drugH1Div" id="F55189622"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Postmarketing reports of <b>bradycardia, </b>including <b>severe bradycardia </b>(some fatal) and sinus bradycardia, have been reported in patients receiving remdesivir for COVID-19. An observational study using data from the WHO pharmacovigilance database found that bradycardia was more likely to be reported with remdesivir treatment than with hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or glucocorticoid treatment, and reports included mostly males in the United States over a wide spectrum of ages (43 to 79 years of age). Most of these patients were not receiving concurrent cardiovascular medications. Other cardiac effects were observed, most notably <b>hypotension</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33647441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33647441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Mechanism: Unknown; it has been suggested that the active metabolite of remdesivir, a nucleotide triphosphate derivative, may slow sinoatrial node automaticity due to its similarity with adenosine triphosphate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33163977','lexi-content-ref-34026493','lexi-content-ref-33647441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33163977','lexi-content-ref-34026493','lexi-content-ref-33647441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Bradycardia: Varied; a median onset of 2.4 days (range: 1 to 6 days) was observed in an observational study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33647441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33647441'])">Ref</a></span>). Other reports have noted onset of bradycardia within 24 hours of administration of first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33163977','lexi-content-ref-34026493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33163977','lexi-content-ref-34026493'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In clinical trials, mild to moderate (grades 1 to 2) reversible transaminase elevations, including <b>increased serum alanine aminotransferase,</b>
<b>increased serum aspartate aminotransferase,</b> and <b>increased serum bilirubin</b>, were observed in healthy volunteers and adult and pediatric patients with COVID-19. <b>Hepatitis</b> (including ischemic) and <b>acute hepatic failure</b> with significant increases in transaminases, coagulopathy, and encephalopathy have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33006138','lexi-content-ref-33940227','lexi-content-ref-32721580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33006138','lexi-content-ref-33940227','lexi-content-ref-32721580'])">Ref</a></span>). It is unclear if these effects are drug-related or related to COVID-19 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33006138','lexi-content-ref-33940227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33006138','lexi-content-ref-33940227'])">Ref</a></span>). Most aminotransferase elevations during treatment for COVID-19 were reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33006138','lexi-content-ref-32707160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33006138','lexi-content-ref-32707160'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; range of 1 to 16 days has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33006138','lexi-content-ref-FDA.1','lexi-content-ref-32721580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33006138','lexi-content-ref-FDA.1','lexi-content-ref-32721580'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity and infusion related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions</b>, including <b>anaphylaxis </b>and <b>infusion related reactions</b>, have been reported during and following remdesivir administration. Patients may experience <b>angioedema</b>, bradycardia, diaphoresis, dyspnea, fever, hypertension, hypotension, hypoxia, <b>nausea</b>, shivering, skin rash, tachycardia, and wheezing. Slower infusion rates (maximum infusion time of up to 120 minutes) may be considered in patients to potentially prevent hypersensitivity or infusion related reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; most commonly occurs within 1 hour.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54340914"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adolescents and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose (grades 3/4: 3% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance (grades 3/4: 2% to 19%), increased serum creatinine (grades 3/4: 3% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (grades 3/4: 1% to 8%), lymphocytopenia (grades 3/4: 2%), prolonged prothrombin time (grades 3/4: 9%)<span class="lexi-table-link-container"> (<a aria-label="Remdesivir: Adverse Reaction: Prolonged Prothrombin Time table link" class="lexi-table-link" data-table-id="lexi-content-remdesivir-adverse-reaction-prolonged-prothrombin-time" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-remdesivir-adverse-reaction-prolonged-prothrombin-time')">table 1</a>)</span><span class="table-link" style="display:none;">Remdesivir: Adverse Reaction: Prolonged Prothrombin Time</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Remdesivir: Adverse Reaction: Prolonged Prothrombin Time" frame="border" id="lexi-content-remdesivir-adverse-reaction-prolonged-prothrombin-time" rules="all">
<caption style="text-align:center;">
<b>Remdesivir: Adverse Reaction: Prolonged Prothrombin Time</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Remdesivir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Remdesivir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg on Day 1 and 100 mg once daily on subsequent days, for 10 days of treatment</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">SARS-CoV-2 infection</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">532</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">516</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2% to 7%), increased serum aspartate aminotransferase (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (including severe bradycardia and sinus bradycardia) (Gubitosa 2020, Jacinto 2021, Touafchia 2021), heart failure (Wang 2020), hypotension (Touafchia 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (Carothers 2020), hepatitis (including ischemic) (Kim 2021, Montastruc 2020), increased serum bilirubin (Kim 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Hopkins 2021)</p></div>
<div class="block coi drugH1Div" id="F54368294"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to remdesivir or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54342497"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>• </b>Renal impairment: Use caution in patients with eGFR &lt;30 mL/minute and assess risk versus benefit based upon dosing information in renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<i>Dosage form specific issues</i>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Contains the excipient cyclodextrin (sulfobutylether-beta-cyclodextrin [SBECD]; 6 g per 100 mg remdesivir [injection solution] or 3 g per 100 mg remdesivir [lyophilized powder]), which may accumulate in patients with renal impairment.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54384377"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Sulfobutylether-beta-cyclodextrin sodium salt (SBECD) is an excipient in remdesivir; SBECD is renally cleared and accumulates in patients with decreased renal function. The lyophilized powder formulation contains 3 g of SBECD per 100 mg remdesivir, while the injection solution 5 mg/mL contains 6 g of SBECD per 100 mg remdesivir. In pediatric patients weighing &lt;40 kg, the manufacturer recommends use of the lyophilized powder only.</p></div>
<div class="block foc drugH1Div" id="F54282129"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veklury: 100 mg/20 mL (20 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea [DSC]); 150 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veklury: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F54282128"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F54335593"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Veklury Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $719.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54783415"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veklury: 100 mg/20 mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veklury: 100 mg (1 ea)</p></div>
<div class="block accres drugH1Div" id="F54175139"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Remdesivir is available to hospitals directly from the distributor AmerisourceBergen (1-800-746-6273 or <a class="__cf_email__" data-cfemail="cdbfa8a0a9a8bea4bba4bf8daca0a8bfa4bea2b8bfaea8afa8bfaaa8a3e3aea2a0" href="/cdn-cgi/l/email-protection">[email protected]</a>); more information is available at https://www.vekluryhcp.com/product-access/. Additionally, health care providers must track and report all medication errors and serious adverse events potentially associated with remdesivir use by either submitting a MedWatch form (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch%2Freport.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPNcm5lNJ%2BSfidIV4m5OTN5Ih2EApxCjHbBkH0Y1jxFob&amp;TOPIC_ID=127259" target="_blank">https://www.fda.gov/medwatch/report.htm</a>) or FDA Form 3500 (health professional) by fax (1-800-FDA-0178); a copy of all MedWatch forms should also be provided to Gilead (<a class="__cf_email__" data-cfemail="ef9c8e898a9b96b0898caf8886838a8e8bc18c8082" href="/cdn-cgi/l/email-protection">[email protected]</a>).</p></div>
<div class="block adm drugH1Div" id="F54368300"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer as an IV infusion over 30 to 120 minutes. May be an irritant; avoid extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33950198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33950198'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F54374553"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer as an IV infusion over 30 to 120 minutes in a setting where it is possible to appropriately manage severe hypersensitivity reactions (such as anaphylaxis). Do not administer simultaneously with any other medication or IV solutions other than NS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). May be an irritant; avoid extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33950198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33950198'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F54980059"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>COVID-19: </b>Treatment of COVID-19 in adult and pediatric patients (28 days of age and older weighing at least 3 kg) who require hospitalization or nonhospitalized patients with mild to moderate COVID-19 at high risk for progression to severe COVID-19, including hospitalization or death. Remdesivir may only be administered in health care settings in which health care providers have immediate access to medications to treat a severe infusion or hypersensitivity reaction, such as anaphylaxis, and the ability to activate the emergency medical system, as necessary.</p></div>
<div class="block mst drugH1Div" id="F54822515"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Remdesivir (Veklury) is available in two formulations for IV administration, a concentrated solution and a lyophilized powder. Each product has different recommendations for storage, preparation for administration, and administration. In addition, the concentrated solution should only be used in adults and pediatric patients weighing ≥40 kg, while the lyophilized powder can be used in adults and pediatric patients weighing ≥3 kg. The Institute for Safe Medication Practices (ISMP) reports that there have been numerous medication errors related to the two formulations available; use caution with product selection and follow appropriate recommendations for the formulation (FDA 2022; ISMP 2020).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54254501"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (minor), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F54254498"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: May diminish the therapeutic effect of Remdesivir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May diminish the therapeutic effect of Remdesivir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Remdesivir may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Remdesivir may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F54285063"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following use of remdesivir in pregnant patients are available from small studies and case reports (Budi 2022; Burwick 2021; Eid 2022; Gutierrez 2022; Jorgensen 2021; Marzban-Rad 2022; Nasrallah 2021; Tavakoli 2023). Based on preliminary data, maternal treatment of COVID-19 infection with remdesivir may decrease vertical transmission to the newborn and decrease NICU admissions of infants of mothers with mild or moderate disease (Tavakoli 2023). In addition, pregnant patients who received early remdesivir treatment (&lt;7 days of symptoms) were less likely to be admitted to the ICU, progress to critical disease, and had shorter hospital stays (Eid 2022). Adverse effects in the mother were similar to those of nonpregnant patients (Burwick 2021).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID-19. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO) compared to symptomatic nonpregnant patients. Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2023).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process. Use of remdesivir is recommended if indicated (NIH 2023). Pregnancy-induced physiologic changes do not alter the pharmacokinetic properties of remdesivir in a clinically significant way; dose adjustments are not recommended. Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor maternal and infant outcomes following exposure to remdesivir during pregnancy is ongoing.</p>
<p style="text-indent:0em;margin-left:2em;">- Pregnant and recently pregnant patients exposed to remdesivir are encouraged to enroll in the registry (800-616-3791 or http://covidpr.pregistry.com)</p>
<p style="text-indent:0em;margin-left:2em;">- Health care providers are encouraged to enroll patients exposed to COVID-19 during pregnancy in the Organization of Teratology Information Specialists (OTIS) pregnancy registry (877-311-8972; https://mothertobaby.org/join-study/).</p></div>
<div class="block brc drugH1Div" id="F54285064"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Remdesivir and the GS-441524 metabolite have been detected in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk concentrations of remdesivir were evaluated in a patient diagnosed with COVID-19 infection 2 days following delivery at 38 weeks' gestation. Remdesivir 200 mg IV was administered on the first day, followed by 100 mg daily for 4 days. The mother had initiated breastfeeding prior to diagnosis and pumped to maintain the milk supply during remdesivir treatment. Breast milk was sampled on treatment day 5 prior to and 1, 3, 6, and 24 hours after remdesivir administration. Concentrations of remdesivir were measurable only in the sample obtained 1 hour prior to administration (1.29 ng/mL; corresponding maternal serum concentration 14.4 ng/mL). Concentrations of the GS-441524 metabolite in breast milk prior to and 24 hours after dosing were 13.5 ng/mL and 64.34 ng/mL; corresponding maternal serum concentrations were 389.9 ng/mL and 201.1 ng/mL, respectively. Metabolite concentrations in breast milk ranged from 13.5 ng/mL to 284.9 ng/mL. The half-life of GS-441524 in breast milk was 9.3 hours. Authors of the study calculated the relative infant dose (RID) of remdesivir to be &lt;1% and the RID of GS-441524 to be 1.55%, concentrations considered acceptable for breastfeeding (Wada 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Breast milk has not been found to be a source of COVID-19 infection and maternal infection is not a contraindication to breastfeeding. However, lactating patients with COVID-19 infection can transmit the virus through respiratory droplets and all precautions should be taken to avoid spreading the virus to the infant (eg, hand hygiene, mask wearing); alternatively, breast milk can be expressed and fed to the infant by someone without confirmed or suspected COVID-19 (ACOG 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to COVID-19 and breastfeeding is available from the World Health Organization (https://www.who.int/news/item/28-04-2020-new-faqs-address-healthcare-workers-questions-on-breastfeeding-and-covid-19).</p></div>
<div class="block mop drugH1Div" id="F54368302"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate (baseline and when clinically indicated) (Touafchia 2021); liver chemistries (ALT, AST, bilirubin, alkaline phosphatase, and prothrombin time at baseline, then every 1 to 2 days for inpatients or when clinically indicated for outpatients); renal function (serum creatinine and CrCl at baseline and periodically during therapy); signs/symptoms of infusion/hypersensitivity reaction (observe patients for at least 1 hour after infusion is complete).</p></div>
<div class="block pha drugH1Div" id="F54175144"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Remdesivir is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. Remdesivir is an adenosine nucleotide prodrug that is metabolized to the pharmacologically active nucleoside triphosphate metabolite after being distributed into cells. Remdesivir triphosphate (GS-443902) acts as an adenosine triphosphate analog and competes for incorporation into RNA chains by the SARS-CoV-2 RdRp, resulting in delayed chain termination during viral RNA replication. Remdesivir triphosphate can also inhibit viral RNA synthesis due to incorporation into the viral RNA template.</p></div>
<div class="block phk drugH1Div" id="F54368313"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Remdesivir: 88% to 93.6%; GS-441524: 2%; GS-704277: 1%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatically, primarily by carboxylesterase 1 (Humeniuk 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Remdesivir: ~1 hour; GS-441524: 27 hours; GS-704277: 1.3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-4em;margin-left:6em;">Urine: Remdesivir: 10%; GS-441524: 49%; GS-704277: 2.9%</p>
<p style="text-indent:-4em;margin-left:6em;">Feces: Remdesivir: Not detected; GS-441524: 0.5%; GS-704277: Not detected.</p></div>
<div class="block phksp drugH1Div" id="F54374522"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">AUC<sub>inf</sub> of remdesivir is not significantly affected by kidney function. AUC<sub>inf </sub>of GS-441524, GS-704277, and SBECD were up to 7.9-fold, 2.8-fold, and 21-fold higher, respectively, in patients with eGFR &lt;15 mL/minute/1.73 m<sup>2</sup> compared to patients with normal kidney function. Per the manufacturer, these changes are not considered clinically significant.</p>
<p style="text-indent:-2em;margin-left:2em;">Expected drug exposure in adults with normal renal function:</p>
<p style="text-indent:-2em;margin-left:4em;">C<sub>max</sub> (peak): IV: 100 mg once daily, steady state: Remdesivir: 2,229 ng/mL; GS-441524: 145 ng/mL; GS-704277: 246 ng/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">C<sub>min</sub> (trough): IV: 100 mg once daily, steady state: Remdesivir: Not detected; GS-441524: 69.2 ng/mL; GS-704277: Not detected.</p>
<p style="text-indent:-2em;margin-left:4em;">AUC: IV: 100 mg once daily, steady state: Remdesivir: 1,585 ng • hour/mL; GS-441524: 2,229 ng • hour/mL; GS-704277: 462 ng • hour/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: In a pharmacokinetic modeling study, exposure to remdesivir and metabolites (C<sub>max</sub>, AUC) was higher in pediatric patients ≥28 days of age weighing ≥3 kg receiving recommended dosing regimens as compared to adults. The difference in exposure is not expected to be clinically significant.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522054"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Bemsivir | Ninavir | Pandovir | Ramdivir | Remcor | Remdinil | Remivir</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Covifor | Ninavir</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Jubi r | Remidia</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cipremi | Covifor | Desrem | Jubi r | Redyx | Remdac | RemWin</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Flexivir | Pandovir</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Rembosch</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Remdeform | Veklury</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Veklury</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Covifor | Desrem</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Corovir | Remcor | Remdessa | Remivir | Remiwell</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Jubi r | Veklury</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29511076">
<a name="29511076"></a>Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease.<i> mBio.</i> 2018;9(2):e00221-18. doi:10.1128/mBio.00221-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/29511076/pubmed" id="29511076" target="_blank">29511076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5277140">
<a name="5277140"></a>Ahrens G. Calcium in human saliva: the significance of physiological and gustatory factors influencing its concentration. <i>Caries Res</i>. 1971;5(1):25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/5277140/pubmed" id="5277140" target="_blank">5277140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33555780">
<a name="33555780"></a>Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. <i>Crit Care Med</i>. Published online January 28, 2021. doi:10.1097/CCM.0000000000004899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33555780/pubmed" id="33555780" target="_blank">33555780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35045989">
<a name="35045989"></a>Ali K, Azher T, Baqi M, et al; Canadian Treatments for COVID-19 (CATCO); Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. <i>CMAJ</i>. 2022;194(7):E242-E251. doi:10.1503/cmaj.211698<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35045989/pubmed" id="35045989" target="_blank">35045989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed April 25, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32445440">
<a name="32445440"></a>Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19 - final report. <i>N Engl J Med</i>. 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32445440/pubmed" id="32445440" target="_blank">32445440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bhimraj.1">
<a name="Bhimraj.1"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America (IDSA) guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated June 29, 2022. Accessed August 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35128114">
<a name="35128114"></a>Budi DS, Pratama NR, Wafa IA, Putra M, Wardhana MP, Wungu CDK. Remdesivir for pregnancy: a systematic review of antiviral therapy for COVID-19. <i>Heliyon</i>. 2022;8(1):e08835. doi:10.1016/j.heliyon.2022.e08835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35128114/pubmed" id="35128114" target="_blank">35128114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33031500">
<a name="33031500"></a>Burwick RM, Yawetz S, Stephenson KE, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019. <i>Clin Infect Dis</i>. 2021;73(11):e3996-e4004. doi:10.1093/cid/ciaa1466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33031500/pubmed" id="33031500" target="_blank">33031500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33006138">
<a name="33006138"></a>Carothers C, Birrer K, Vo M. Acetylcysteine for the treatment of suspected remdesivir-associated acute liver failure in COVID-19: a case series. <i>Pharmacotherapy</i>. Published online October 2, 2020. doi:10.1002/phar.2464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33006138/pubmed" id="33006138" target="_blank">33006138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32918548">
<a name="32918548"></a>Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. <i>J Pediatric Infect Dis Soc</i>. 2021;10(1):34-48. doi:10.1093/jpids/piaa115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32918548/pubmed" id="32918548" target="_blank">32918548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34173663">
<a name="34173663"></a>Chow EJ, Maust B, Kazmier KM, Stokes C. Sinus bradycardia in a pediatric patient treated with remdesivir for acute coronavirus disease 2019: a case report and a review of the literature. <i>J Pediatric Infect Dis Soc</i>. 2021;10(9):926-929. doi:10.1093/jpids/piab029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/34173663/pubmed" id="34173663" target="_blank">34173663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35134032">
<a name="35134032"></a>Eid J, Abdelwahab M, Colburn N, et al. Early administration of remdesivir and intensive care unit admission in hospitalized pregnant individuals with Coronavirus disease 2019 (COVID-19). <i>Obstet Gynecol.</i> Published online February 8, 2022. doi:10.1097/AOG.0000000000004734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35134032/pubmed" id="35134032" target="_blank">35134032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32554811">
<a name="32554811"></a>Frauenfelder C, Brierley J, Whittaker E, Perucca G, Bamford A. Infant with SARS-CoV-2 infection causing severe lung disease treated with remdesivir. <i>Pediatrics</i>. 2020;146(3):e20201701. doi:10.1542/peds.2020-1701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32554811/pubmed" id="32554811" target="_blank">32554811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilead.1">
<a name="Gilead.1"></a>Gilead Sciences Inc. Pediatrics and remdesivir [written communication]. Foster City, CA: Gilead Sciences Inc; May 8, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilead.2">
<a name="Gilead.2"></a>Gilead Sciences Inc. Questions re: remdesivir [written communication]. Foster City, CA: Gilead Sciences Inc; May 19, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilead.3">
<a name="Gilead.3"></a>Gilead Sciences Inc. Update on the company's ongoing response to COVID-19. https://www.gilead.com/purpose/advancing-global-health/covid-19. Accessed September 2, 2020c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilead.4">
<a name="Gilead.4"></a>Gilead Sciences Inc. Veklury (remdesivir) compatibility with alternative diluents. https://www.askgileadmedical.com/api/rendition.php?doc=17818. Updated January 10, 2022. Accessed January 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilead.5">
<a name="Gilead.5"></a>Gilead Sciences Inc. Veklury (remdesivir) overfill during dose preparation. https://www.askgileadmedical.com. Updated October 23, 2020d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33883243">
<a name="33883243"></a>Goldman DL, Aldrich ML, Hagmann SHF, et al. Compassionate use of remdesivir in children with severe COVID-19. <i>Pediatrics</i>. 2021;147(5):e2020047803. doi:10.1542/peds.2020-047803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33883243/pubmed" id="33883243" target="_blank">33883243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459919">
<a name="32459919"></a>Goldman JD, Lye DCB, Hui DS, et al; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19. <i>N Engl J Med</i>. 2020;383(19):1827-1837. doi:10.1056/NEJMoa2015301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32459919/pubmed" id="32459919" target="_blank">32459919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34937145">
<a name="34937145"></a>Gottlieb RL, Vaca CE, Paredes R, et al; GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe Covid-19 in outpatients. <i>N Engl J Med</i>. Published online December 22, 2021. doi:10.1056/NEJMoa2116846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/34937145/pubmed" id="34937145" target="_blank">34937145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33163977">
<a name="33163977"></a>Gubitosa JC, Kakar P, Gerula C, et al. Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. <i>JACC Case Rep</i>. 2020;2(14):2260-2264. doi:10.1016/j.jaccas.2020.08.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33163977/pubmed" id="33163977" target="_blank">33163977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35168447">
<a name="35168447"></a>Gutierrez R, Mendez-Figueroa H, Biebighauser JG, Bhalwal A, Pineles BL, Chauhan SP. Remdesivir use in pregnancy during the SARS-CoV-2 pandemic. <i>J Matern Fetal Neonatal Med</i>. 2022:1-7. doi:10.1080/14767058.2022.2041595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35168447/pubmed" id="35168447" target="_blank">35168447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33362383">
<a name="33362383"></a>Hanafy AS, Abd-Elsalam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: a hepatology perspective. <i>World J</i>
<i>Gastroenterol</i>. 2020;26(46):7272-7286. doi:10.3748/wjg.v26.i46.7272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33362383/pubmed" id="33362383" target="_blank">33362383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32004427">
<a name="32004427"></a>Holshue ML, DeBolt C, Lindquist S, et al; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. <i>N Engl J Med</i>. 2020;382(10):929-936. doi:10.1056/NEJMoa2001191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32004427/pubmed" id="32004427" target="_blank">32004427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33593840">
<a name="33593840"></a>Hopkins BJ, Prokesch BC. Anaphylaxis due to remdesivir. <i>Antimicrob Agents Chemother</i>. 2021;65(5):e00233-21. doi:10.1128/AAC.00233-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33593840/pubmed" id="33593840" target="_blank">33593840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33782830">
<a name="33782830"></a>Humeniuk R, Mathias A, Kirby BJ, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor. <i>Clin Pharmacokinet.</i> 2021;60(5):569-583. doi:10.1007/s40262-021-00984-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33782830/pubmed" id="33782830" target="_blank">33782830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). Reported medication errors with Veklury (remdesivir) Emergency Use Authorization. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2020;25(18):1-2.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34026493">
<a name="34026493"></a>Jacinto JP, Patel M, Goh J, Yamamura K. Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease. <i>HeartRhythm Case Rep</i>. 2021;7(8):514-517. doi:10.1016/j.hrcr.2021.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/34026493/pubmed" id="34026493" target="_blank">34026493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707160">
<a name="32707160"></a>Javorac D, Grahovac L, Manić L, et al. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. <i>Food Chem Toxicol</i>. 2020;144:111639. doi:10.1016/j.fct.2020.111639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32707160/pubmed" id="32707160" target="_blank">32707160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34427297">
<a name="34427297"></a>Jorgensen SCJ, Davis MR, Lapinsky SE. A review of remdesivir for COVID-19 in pregnancy and lactation. <i>J Antimicrob Chemother</i>. 2021;77(1):24-30. doi:10.1093/jac/dkab311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/34427297/pubmed" id="34427297" target="_blank">34427297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32446287">
<a name="32446287"></a>Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. <i>Pharmacotherapy</i>. 2020;40(7):659-671. doi:10.1002/phar.2429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32446287/pubmed" id="32446287" target="_blank">32446287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35433235">
<a name="35433235"></a>Kalani-Moghaddam F, Pouralizadeh N, Pourdowlat G, Sarfarazi-Moghaddam S, Gharib MH, Pakdel M. The youngest surviving COVID-19 patient: A case report. <i>Int J Surg Case Rep</i>. 2022;94:107065. doi:10.1016/j.ijscr.2022.107065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35433235/pubmed" id="35433235" target="_blank">35433235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33940227">
<a name="33940227"></a>Kim MS, Jung SY, Lee SW, et al. Hepatobiliary adverse drug reactions associated with remdesivir: the WHO international pharmacovigilance study. <i>Clin Gastroenterol Hepatol</i>. 2021;19(9):1970-1972.e3. doi:10.1016/j.cgh.2021.04.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33940227/pubmed" id="33940227" target="_blank">33940227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35506126">
<a name="35506126"></a>Marzban-Rad S, Ghafarzadeh M, Bahmani S, Kazemi A. The use of remdesivir among pregnant women and associated clinical outcomes in mother and the child. <i>Ann Med Surg (Lond).</i> 2022;77:103681. doi:10.1016/j.amsu.2022.103681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35506126/pubmed" id="35506126" target="_blank">35506126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32721580">
<a name="32721580"></a>Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of remdesivir for coronavirus 2019. <i>Clin Gastroenterol Hepatol</i>. 2020;18(12):2835-2836. doi:10.1016/j.cgh.2020.07.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32721580/pubmed" id="32721580" target="_blank">32721580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33771091">
<a name="33771091"></a>Nasrallah S, Nguyen AQ, Hitchings L, et al. Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. <i>J Matern Fetal Neonatal Med</i>. 2021:1-8. doi:10.1080/14767058.2021.1903426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33771091/pubmed" id="33771091" target="_blank">33771091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIAID.1">
<a name="NIAID.1"></a>National Institute of Allergy and Infectious Diseases (NIAID). NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. <a href="https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19National" target="_blank">https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19National</a>. Accessed May 1, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2">
<a name="NIH.2"></a>National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. September 26, 2022. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32706859">
<a name="32706859"></a>Olender SA, Perez KK, Go AS, et al; GS-US-540–5773 and GS-US-540–5807 Investigators. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. <i>Clin Infect Dis</i>. 2021;73(11):e4166-e4174. doi:10.1093/cid/ciaa1041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32706859/pubmed" id="32706859" target="_blank">32706859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33833623">
<a name="33833623"></a>Parsons S, Tran VL. The trilogy of SARS-CoV-2 in pediatrics (part 1): acute COVID-19 in special populations. <i>J Pediatr Pharmacol Ther</i>. 2021;26(3):220-239. doi:10.5863/1551-6776-26.3.220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33833623/pubmed" id="33833623" target="_blank">33833623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5277141">
<a name="5277141"></a>Paunio IK, Mäkinen KK. Formation and properties of arylaminopeptidases of a cariogenic streptococcus. <i>Caries Res</i>. 1971;5(1):25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/5277141/pubmed" id="5277141" target="_blank">5277141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34591799">
<a name="34591799"></a>Rau C, Apostolidou S, Singer D, Avataneo V, Kobbe R. Remdesivir, sinus bradycardia and therapeutic drug monitoring in children with severe COVID-19. <i>Pediatr Infect Dis J</i>. 2021;40(12):e528-e529. doi:10.1097/INF.0000000000003309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/34591799/pubmed" id="34591799" target="_blank">34591799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saikia.1">
<a name="Saikia.1"></a>Saikia B, Bandi S. RE: Remdesivir use in premature neonates with SARS-CoV-2 infection. https://pediatrics.aappublications.org/content/re-remdesivir-use-premature-neonates-sars-cov-2-infection. Published April 29, 2021a. Accessed September 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33847299">
<a name="33847299"></a>Saikia B, Tang J, Robinson S, et al. Neonates with SARS-CoV-2 infection and pulmonary disease safely treated with remdesivir. <i>Pediatr Infect Dis J</i>. 2021b;40(5):e194-e196. doi:10.1097/INF.0000000000003081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33847299/pubmed" id="33847299" target="_blank">33847299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35213865">
<a name="35213865"></a>Sarhan MA, Casalino M, Paopongsawan P, et al. SARS-CoV-2 associated respiratory failure in a preterm infant and the outcome after remdesivir treatment. <i>Pediatr Infect Dis J</i>. 2022;41(5):e233-e234. doi:10.1097/INF.0000000000003504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35213865/pubmed" id="35213865" target="_blank">35213865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28659436">
<a name="28659436"></a>Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <i>Sci Transl Med.</i> 2017;9(396):eaal3653. doi:10.1126/scitranslmed.aal3653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/28659436/pubmed" id="28659436" target="_blank">28659436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31924756">
<a name="31924756"></a>Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <i>Nat Commun</i>. 2020;11(1):222. doi:10.1038/s41467-019-13940-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/31924756/pubmed" id="31924756" target="_blank">31924756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36782188">
<a name="36782188"></a>Tavakoli N, Chaichian S, Sadraei JS, et al. Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID-19? <i>BMC Pregnancy Childbirth</i>. 2023;23(1):110. doi:10.1186/s12884-023-05405-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/36782188/pubmed" id="36782188" target="_blank">36782188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33647441">
<a name="33647441"></a>Touafchia A, Bagheri H, Carrié D, Durrieu G, Sommet A, Montastruc F. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. <i>Clin Microbiol Infect</i>. 2021;27(5):791.e5-791.e8. doi:10.1016/j.cmi.2021.02.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33647441/pubmed" id="33647441" target="_blank">33647441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33712855">
<a name="33712855"></a>Umemura T, Nishikawa K, Mutoh Y, et al. Usage experience of remdesivir for SARS-CoV-2 infection in a patient with chronic cirrhosis of Child-Pugh class C. <i>J Antimicrob Chemother</i>. 2021;76(7):1947-1948. doi:10.1093/jac/dkab076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33712855/pubmed" id="33712855" target="_blank">33712855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS). HHS announces shipments of donated remdesivir for hospitalized patients with COVID-19. <a href="https://www.hhs.gov/about/news/2020/05/09/hhs-ships-first-doses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html" target="_blank">https://www.hhs.gov/about/news/2020/05/09/hhs-ships-first-doses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html</a>. Accessed May 12, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for health care providers Emergency Use Authorization (EUA) of Veklury<sup>®</sup> (remdesivir). <a href="https://www.fda.gov/media/137566/download" target="_blank">https://www.fda.gov/media/137566/download</a>. Updated January 2022. Accessed January 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). Frequently asked questions on the Emergency Use Authorization for Veklury® (remdesivir) for hospitalized COVID-19 patients. <a href="https://www.fda.gov/media/137574/download" target="_blank">https://www.fda.gov/media/137574/download</a>. Updated October 22, 2020. Accessed October 27, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33763917">
<a name="33763917"></a>van Laar SA, de Boer MGJ, Gombert-Handoko KB, Guchelaar HJ, Zwaveling J; LUMC-Covid-19 Research Group. Liver and kidney function in patients with Covid-19 treated with remdesivir. <i>Br J Clin Pharmacol</i>. 2021;87(11):4450-4454. doi:10.1111/bcp.14831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33763917/pubmed" id="33763917" target="_blank">33763917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33950198">
<a name="33950198"></a>van Merendonk LN, Leeuwerik AF, den Brok MWJ, et al. Peripheral infiltration of remdesivir in 3 patients with COVID-19: case series and discussion. <i>Am J Health Syst Pharm</i>. 2021;78(21):1944-1951. doi:10.1093/ajhp/zxab197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/33950198/pubmed" id="33950198" target="_blank">33950198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Veklury.1">
<a name="Veklury.1"></a>Veklury (remdesivir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35189734">
<a name="35189734"></a>Wada YS, Saito J, Hashii Y, et al. Remdesivir and human milk: a case study. <i>J Hum Lact</i>. Published online February 21, 2022. doi:10.1177/08903344221076539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35189734/pubmed" id="35189734" target="_blank">35189734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32423584">
<a name="32423584"></a>Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. <i>Lancet</i>. 2020;395(10236):1569-1578. doi:10.1016/S0140-6736(20)31022-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32423584/pubmed" id="32423584" target="_blank">32423584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32645175">
<a name="32645175"></a>Wardell H, Campbell JI, VanderPluym C, Dixit A. Severe acute respiratory syndrome coronavirus 2 infection in febrile neonates. <i>J Pediatric Infect Dis Soc</i>. 2020;9(5):630-635. doi:10.1093/jpids/piaa084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32645175/pubmed" id="32645175" target="_blank">32645175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35318694">
<a name="35318694"></a>Wong CKH, Au ICH, Cheng WY, et al. Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study. <i>Aliment Pharmacol Ther</i>. 2022;56(1):121-130. doi:10.1111/apt.16894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/35318694/pubmed" id="35318694" target="_blank">35318694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO R&amp;D Blueprint – Ad-hoc expert consultation on clinical trials for Ebola Therapeutics: Appendix 4. Summaries of evidence from selected experimental therapeutics, as of October 2018. https://www.who.int/ebola/drc-2018/summaries-of-evidence-experimental-therapeutics.pdf?ua=1. Published October 11, 2018. Accessed March 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline. Updated November 20, 2020. Accessed December 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32725454">
<a name="32725454"></a>Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. <i>Hepatol Int</i>. 2020;14(5):881-883. doi:10.1007/s12072-020-10077-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/remdesivir-drug-information/abstract-text/32725454/pubmed" id="32725454" target="_blank">32725454</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 127259 Version 178.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
